Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. 

Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. 

Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

INmuneBIO

OrbiMed

Polaris Partners

Mission Bay Capital

Section 32 Mission BioCapital

Casdin Capital

Google Ventures

Deerfield Capital Management

Euclidean Capital

Amgen Ventures

Alector

2023 was an exceptional year for Alector. Patients & their families were at the forefront of our minds as we executed on our mission and moved closer to achieving our ambitious vision of making brain disorders history. Below, Alector leaders Arnon Rosenthal and Sara Kenkare-Mitra share their reflections on this year as we head into #2024.

Last week, Alector hosted two R&D webinars for analysts, investors & industry on our targets TREM2 and PGRN and shared the significant progress we have made across our clinical programs. We were joined by esteemed thought leaders in the field who contributed to an invaluable dialog. You can catch up on the conversation at the link below. 

Alector continues to be a pioneer in immuno-neurology, and we are excited about the potential to make a difference in the lives of people with #neurodegenerative diseases. 

https://lnkd.in/eARBjk6

During this season of gratitude, we're reminded how lucky we are to have the opportunity to #giveback to our local community. We partnered with Family Giving Tree once again this holiday season to collect gifts and funds for local families in need. We're inspired by the incredibly valuable work organizations like these do. 🎁

The holidays offer a unique opportunity to remind loved ones how much we care about them through gifts or quality time. Taking care of our brain health becomes increasingly important as we grow older. Check out Alector’s top 6 evidence-based holiday gift ideas for enhancing cognitive reserve and lowering risk of #dementia.

Sources: https://lnkd.in/es7R7PAD

The commitment to advocating for, and caring for, people living with a #neurodegenerative disease does not stop, regardless of the season. This winter, we continue to be in awe of our advocacy group partners and their dedication to patients and their families. Thank you for all you do.

NASDAQ:ALEC

Alector, Inc.

Last Close

5.20

25/09 14:38

Market Cap

483.85M

Beta: 0.78

Volume Today

78.22K

Avg: 539.84K

PE Ratio

−3.58

PFCF: −2.67

Analysis Not Available